Gastroesophageal Reflux Disease (GERD) and Proton Pump Inhibitors (PPIs)

GERD arises when the anti-reflux barrier at the gastroesophageal junction is compromised by transient lower esophageal sphincter relaxations, hypotensive sphincter tone, or anatomic disruption such as hiatal hernia. Gastric acidity, pepsin, and occasionally bile can contact the esophageal mucosa, leading to symptoms and mucosal injury. Population studies estimate a global prevalence near 13%, with heartburn and regurgitation as cardinal symptoms and recognized extra-esophageal manifestations (chronic cough, laryngitis, asthma flares, sleep disruption). In clinical practice, a short therapeutic trial of a proton pump inhibitor (PPI) is a common first step for typical symptoms without alarm features. PPIs irreversibly block the parietal cell H+/K+-ATPase, producing potent, sustained acid suppression. High-quality evidence shows PPIs outperform H2 receptor antagonists for healing erosive esophagitis and relieving symptoms over 4–8 weeks. Patients with severe erosive disease or Barrett’s esophagus often require long-term maintenance at the lowest effective dose; patients with non-erosive disease may do well with on-demand or step-down strategies. When symptoms persist despite optimized dosing and correct timing relative to meals, clinicians reassess adherence, consider alternative mechanisms (reflux hypersensitivity, functional heartburn, eosinophilic esophagitis), and use objective testing (endoscopy, ambulatory pH impedance monitoring). Lifestyle measures—weight loss in those with overweight or obesity, head-of-bed elevation, avoiding late meals, and individualized trigger management—have supportive evidence, particularly for nocturnal reflux. Adjuncts such as alginates can reduce postprandial reflux. Safety considerations with chronic PPI therapy are nuanced: common minor adverse effects include headache and gastrointestinal upset; observational data link PPIs with enteric infections (notably C. difficile) and suggest associations with fractures, chronic kidney disease, and micronutrient abnormalities (B12, magnesium), but causality is uncertain for several outcomes. The absolute risk increases are generally small. Rebound acid hypersecretion may produce transient symptom flare after stopping PPIs, so tapering and bridge strategies (H2 blockers, alginates, lifestyle) are often employed. Clinicians periodically reevaluate the indication and consider de-prescribing when appropriate; conversely, ongoing therapy is warranted for high-risk indications such as severe erosive esophagitis, strictures, or Barrett’s esophagus. Surgical options (fundoplication, magnetic sphincter augmentation) or endoscopic therapies are discussed for patients with proven reflux who remain symptomatic or prefer non-pharmacologic durable solutions.

Traditional frameworks view GERD as a systemic imbalance in digestive function. In Traditional Chinese Medicine, reflux often reflects “rebellious Stomach qi” driven by Liver qi stagnation, diet-related Damp-Heat, or Spleen qi deficiency. Treatment aims to harmonize the Liver and Stomach, descend qi, and protect the mucosa. Practitioners may use formulas such as Zuo Jin Wan (Coptis and Evodia) to address acid regurgitation, or modify tonifying formulas when deficiency patterns predominate. Acupuncture points including PC6 (Neiguan), ST36 (Zusanli), and CV12 (Zhongwan) are selected to regulate motility, reduce nausea, and calm the autonomic nervous system. Evidence, while limited, suggests acupuncture can improve reflux symptoms and quality of life, and small trials indicate diaphragmatic breathing decreases transient LES relaxations and reflux episodes. Ayurveda conceptualizes reflux under Amlapitta, an aggravation of Pitta (heat/acid) with impaired Agni (digestive fire). Care emphasizes cooling, non-spicy foods, mindful eating, earlier dinners, and herbs like Yashtimadhu (licorice), Amalaki, and Guduchi to soothe and restore balance. Naturopathic and Western herbal traditions converge on demulcent botanicals—deglycyrrhizinated licorice, slippery elm, and marshmallow root—to coat and comfort the esophageal lining; multi-herb preparations like Iberogast (STW‑5) have clinical data in functional dyspepsia and may help overlap symptoms. Integrative clinicians often pair a finite PPI course to heal erosions with lifestyle, botanicals, and stress regulation, then attempt a careful taper while monitoring for rebound symptoms. They also caution about herb–drug interactions (for example, glycyrrhizin-containing licorice can raise blood pressure and potassium loss) and tailor choices to comorbidities. Across traditions, shared pillars include attention to meal timing (earlier, lighter evening meals), body weight optimization, smoking cessation, and stress reduction. These measures complement pharmacologic therapy and, for selected patients with documented reflux, can help sustain symptom control when stepping down PPI therapy under medical supervision.